Syneron Medical (Nasdaq: ELOS) is expected to report Q1 earnings on May 22. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Syneron Medical's revenues will shrink -2.4% and EPS will turn positive

The average estimate for revenue is $61.2 million. On the bottom line, the average EPS estimate is $0.02.

Revenue details
 Last quarter, Syneron Medical booked revenue of $72.8 million. GAAP reported sales were 19% higher than the prior-year quarter's $61.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.11. GAAP EPS were $0.14 for Q4 compared to -$0.23 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 49.5%, 30 basis points better than the prior-year quarter. Operating margin was 0.7%, much worse than the prior-year quarter. Net margin was 7.1%, much better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $289.9 million. The average EPS estimate is $0.47.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 700 members out of 732 rating the stock outperform, and 32 members rating it underperform. Among 178 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 172 give Syneron Medical a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Syneron Medical is buy, with an average price target of $16.38.

Is Syneron Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.